MarginsXMarginsX
Home › Markets › Health Care › GRFS

Grifols S.A. (GRFS)

GRFS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$8.73
+0.46% on the day
Market cap
$6.0B
Mid cap
Revenue · 2025
$8.3B
+4.3% on 2024
Net income · 2025
$444.3M
5.3% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1438569/000110465926044901/0001104659-26-044901-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31. Converted from EUR at 0.9048 per USD (today's ECB or Federal Reserve reference rate).

Profile

FieldValue
TickerGRFS on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountrySpain
IPO yearNot reported by the screener
SEC CIK0001438569

Financials · 2025

LineValue
Revenue$8.3B
Net income$444.3M
Operating income$1.4B
Net margin5.3%
Operating margin16.5%
Revenue growth+4.3%
Cash$911.8M
Total assets$21.8B
P/E (computed)13.5×
P/S (computed)0.7×

Reported in EUR; shown in US dollars.

Warning signs

Cash runway
Cash-flow positive
825.0M EUR cash at December 31, 2025
Share count, 1 year
See the dilution note
Going-concern doubt
No
20-F filed April 17, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-17
Cash and burn825.0M EUR cash; operating cash flow 261.8M EUR a quarter.Report 2025-12-31
Shares outstandingNo cover-page share count in XBRLCover page 2025-12-31
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDeloitte Auditores, S.L., Barcelona, SpainPCAOB Form AP 2026-05-21
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
7.5B EUR402.0M EUR1.0B EUR825.0M EUR160K EUR7.5B EUR20-F 2026-04-17
FY 2024
2024-12-31
7.2B EUR156.9M EUR902.2M EUR979.8M EUR318.2M EUR7.2B EUR20-F 2025-04-11
FY 2023
2023-12-31
6.6B EUR42.3M EUR218.7M EUR529.6M EUR674.3M EUR6.6B EUR20-F 2025-04-11
FY 2022
2022-12-31
6.1B EUR185.0M EUR-1.4M EUR549.2M EUR449.4M EUR6.1B EUR20-F 2025-04-11
FY 2021
2021-12-31
4.9B EUR188.7M EUR597.0M EUR2.7B EUR330.0M EUR4.9B EUR20-F 2024-04-19
FY 2020
2020-12-31
5.3B EUR618.5M EUR1.1B EUR579.6M EUR169.6M EUR5.3B EUR20-F 2023-04-18
FY 2019
2019-12-31
5.1B EUR625.1M EUR568.9M EUR742.0M EUR186.0M EUR5.1B EUR20-F 2022-04-29
FY 2018
2018-12-31
4.5B EUR596.6M EUR737.4M EUR1.0B EUR154.8M EUR4.5B EUR20-F 2021-04-09

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in EUR.

Key SEC documents

The SEC filing list did not load in time for this page. It is on SEC EDGAR and in the full dossier.

Price moves

WindowReturn
1 week+3.1%
1 month+21.2%
3 months+9.6%
Year to date-7.1%
1 year-0.1%
From 52-week high-10.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SUPNSupernus Inc.$28.83-2.99%$6.0B
MIRMMirum Pharmaceuticals Inc.$91.58-2.56%$6.0B
LGNDLigand Pharmaceuticals Incorporated$301.71-2.29%$6.0B
ARWRArrowhead Pharmaceuticals Inc.$44.21-7.47%$6.2B
BLTEBelite Bio Inc$162.56-1.09%$6.5B
MANEVeradermics Incorporated$128.05-1.24%$5.4B
ERASErasca Inc.$15.11-3.51%$5.3B
PTCTPTC Therapeutics Inc.$60.97-3.97%$5.1B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier